Systematic design of multiplex methylation-specific qPCR for cancer related biomarkers

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Analysis of circulating cell-free DNA (cfDNA) methylation abnormalities has emerged as a powerful strategy for detecting various diseases, particularly cancers. This study demonstrates a process for developing a multiplex methylation-specific qPCR assay for cancer biomarker detection.

Abstract

Analysis of circulating cell-free DNA (cfDNA) methylation abnormalities has emerged as a promising strategy for detecting various diseases, including cancer. While single-biomarker approaches may lack sensitivity, comprehensive next-generation sequencing (NGS) can be cumbersome and expensive. Multiplex methylation qPCR assays offer a practical intermediate solution by providing accurate, accessible, and affordable methylation biomarker detection. In this study, we demonstrated a process for developing a multiplex methylation-specific qPCR assay using colorectal cancer (CRC) methylation biomarkers as a case study. Starting with a set of CRC methylation biomarkers, we developed the Multiplex Methylation-specific qPCR (MMqPCR) algorithm to scan differentially methylated regions (DMRs) for methylation-specific PCR primer and probe design. We then established a systematic process to eliminate assay cross-reactions, reduce background noise, and assess multiplex compatibility. Using a low concentration of hypermethylated DNA (0.1%) in a digital analysis, we demonstrated a 95.8% detection rate with the multiplex strategy, significantly outperforming the singleplex approach (47.9%). The multiplex qPCR development principles and automated primer design algorithm presented here provide valuable tools for developing disease screening, detection or monitoring methods based on methylation analysis.

Article activity feed